vs
Side-by-side financial comparison of Five9, Inc. (FIVN) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Five9, Inc. is the larger business by last-quarter revenue ($300.3M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). On growth, Five9, Inc. posted the faster year-over-year revenue change (7.8% vs 5.0%). Over the past eight quarters, Five9, Inc.'s revenue compounded faster (10.3% CAGR vs -0.2%).
Five9, Inc. is a leading global provider of cloud-native contact center software and solutions. It serves enterprises of all sizes across retail, healthcare, financial services, and technology sectors, offering omnichannel customer engagement tools, AI-powered automation, workforce management, and analytics to boost customer experience and operational efficiency.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FIVN vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $300.3M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | 55.4% | — |
| Operating Margin | 6.6% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | 7.8% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.22 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $300.3M | $196.9M | ||
| Q3 25 | $285.8M | $179.5M | ||
| Q2 25 | $283.3M | $181.1M | ||
| Q1 25 | $279.7M | $168.9M | ||
| Q4 24 | $278.7M | $187.3M | ||
| Q3 24 | $264.2M | $168.6M | ||
| Q2 24 | $252.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $18.0M | $5.4M | ||
| Q2 25 | $1.2M | $-4.8M | ||
| Q1 25 | $576.0K | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-4.5M | $-143.5M | ||
| Q2 24 | $-12.8M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 55.4% | 79.5% | ||
| Q3 25 | 55.0% | 80.9% | ||
| Q2 25 | 54.9% | 77.4% | ||
| Q1 25 | 55.0% | 79.7% | ||
| Q4 24 | 56.0% | 78.7% | ||
| Q3 24 | 53.8% | 76.9% | ||
| Q2 24 | 53.0% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 6.6% | 1.2% | ||
| Q3 25 | 5.6% | 3.5% | ||
| Q2 25 | -0.6% | 4.7% | ||
| Q1 25 | -1.9% | 1.2% | ||
| Q4 24 | 1.5% | 13.2% | ||
| Q3 24 | -5.8% | -82.8% | ||
| Q2 24 | -7.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 6.3% | 3.0% | ||
| Q2 25 | 0.4% | -2.7% | ||
| Q1 25 | 0.2% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.7% | -85.1% | ||
| Q2 24 | -5.1% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.22 | $0.05 | ||
| Q3 25 | $0.21 | $0.12 | ||
| Q2 25 | $0.01 | $-0.11 | ||
| Q1 25 | $0.01 | $0.10 | ||
| Q4 24 | $0.16 | $0.38 | ||
| Q3 24 | $-0.06 | $-3.11 | ||
| Q2 24 | $-0.17 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $232.1M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $785.8M | $653.9M |
| Total Assets | $1.8B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $232.1M | $238.4M | ||
| Q3 25 | $193.4M | $246.3M | ||
| Q2 25 | $205.5M | $445.9M | ||
| Q1 25 | $370.3M | $493.6M | ||
| Q4 24 | $362.5M | $484.6M | ||
| Q3 24 | $291.0M | $453.8M | ||
| Q2 24 | $175.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $785.8M | $693.1M | ||
| Q3 25 | $775.3M | $727.2M | ||
| Q2 25 | $717.4M | $757.8M | ||
| Q1 25 | $664.3M | $798.5M | ||
| Q4 24 | $622.2M | $778.3M | ||
| Q3 24 | $565.6M | $749.6M | ||
| Q2 24 | $525.9M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.8B | $1.3B | ||
| Q3 25 | $1.8B | $1.3B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $2.1B | $1.6B | ||
| Q4 24 | $2.1B | $1.6B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $1.9B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $83.6M | — |
| Free Cash FlowOCF − Capex | $77.3M | — |
| FCF MarginFCF / Revenue | 25.8% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $201.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $83.6M | $43.7M | ||
| Q3 25 | $59.2M | $60.8M | ||
| Q2 25 | $35.1M | $12.0M | ||
| Q1 25 | $48.4M | $35.5M | ||
| Q4 24 | $49.8M | $33.1M | ||
| Q3 24 | $41.1M | $53.9M | ||
| Q2 24 | $19.9M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $77.3M | $43.5M | ||
| Q3 25 | $48.7M | $57.0M | ||
| Q2 25 | $31.6M | $9.3M | ||
| Q1 25 | $43.7M | $26.9M | ||
| Q4 24 | $40.5M | $31.0M | ||
| Q3 24 | $26.7M | $49.8M | ||
| Q2 24 | $13.1M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 25.8% | 22.1% | ||
| Q3 25 | 17.0% | 31.7% | ||
| Q2 25 | 11.1% | 5.1% | ||
| Q1 25 | 15.6% | 15.9% | ||
| Q4 24 | 14.5% | 16.6% | ||
| Q3 24 | 10.1% | 29.6% | ||
| Q2 24 | 5.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.1% | ||
| Q3 25 | 3.7% | 2.2% | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 1.7% | 5.1% | ||
| Q4 24 | 3.3% | 1.1% | ||
| Q3 24 | 5.4% | 2.4% | ||
| Q2 24 | 2.7% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.29× | 11.20× | ||
| Q2 25 | 30.38× | — | ||
| Q1 25 | 84.00× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FIVN
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
